3. Results
±
A total of 102 patients were subjected to randomization. Among these, 99 successfully completed both the baseline and follow-up laboratory evaluations, as depicted in The baseline characteristics of patients assigned to the omega-3 fatty acids and placebo groups displayed no significant differences in most parameters, indicating comparable groups at the study’s initiation. Subgroup analysis, however, did reveal significant differences in lipid profiles associated with PPARG polymorphisms. Specifically, patients with PPARG polymorphisms exhibited higher baseline levels of certain lipids.The mean baseline LDL-C level was higher in patients with PPARG polymorphisms (135.3 ± 23.2 mg/dL) compared to those without (123.7 ± 19.3 mg/dL, Similarly, mean HDL-C levels differed (52.4 ± 13.5 mg/dL for those with polymorphisms vs. 61.9 ± 16.6 mg/dL for those without, Total cholesterol levels also showed significant differences (215 ± 25 mg/dL for patients with polymorphisms vs. 200 ± 22 mg/dL for those without, Triglyceride levels were 160 ± 35 mg/dL for those with PPARG polymorphisms compared to 140 ± 25 mg/dL for those without (The hsCRP levels did not differ significantly between the subgroups (2.5 ± 1.7 mg/L for patients with polymorphisms vs. 1.9 ± 1.3 mg/L for those without, These findings are detailed in 